Krystallenia Alexandraki

Dr. Krystallenia Alexandraki

Endocrine Unit, 1st Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2006 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
Christina PiperiChristina Piperi
Christina Piperi
CKChristos Kalofoutis
Christos Kalofoutis
JSJaipaul Singh
Jaipaul Singh
AAAntonis Alaveras
Antonis Alaveras
AKAnastasios Kalofoutis
Anastasios Kalofoutis

23 February 2006 in Human Reproduction
Verified
Journal Article
Open access
PDF file
Evanthia Diamanti-KandarakisEvanthia Diamanti-Kandarakis
Evanthia Diamanti-Kandarakis
TPThomas Paterakis
Thomas Paterakis
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
Christina PiperiChristina Piperi
Christina Piperi
AAAthanasios Aessopos
Athanasios Aessopos
DPDimitrios Panidis
Dimitrios Panidis
BACKGROUND: Women with polycystic ovary syndrome (PCOS) have an increased prevalence of insulin resistance (IR) and related disorders. Elevated serum levels of cellular adhesion molecules (CAMs) reflect low-grade chronic inflammation and have been associated with several insulin-resistant states. The objective of this study is to investigate whether soluble inflammatory markers [soluble intercellular adhesion molecule-1 (sICAM-1), soluble endothelial leukocyte adhesion molecule-1 (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1) and C-reactive protein (CRP)] are altered in PCOS and to further elucidate the effect of metformin treatment on their levels. METHODS: Two young populations were studied [62 women with PCOS and 45 normal women of similar age, BMI and waist-to-hip ratio (WHR)]. Plasma levels of sICAM-1, sVCAM-1, sE-selectin and high-sensitivity CRP (hsCRP) were measured in both groups. Additionally, the effect of metformin on these molecules was investigated in 22 women with PCOS who accepted to metformin protocol (1700 mg daily for a 6-month period). RESULTS: In the total population studied, plasma levels of hsCRP (mg/l), sICAM-1 (ng/ml) and sE-selectin (ng/ml) were higher in the PCOS group compared with those in controls (hsCRP 1.31 ± 0.22 versus 0.92 ± 0.27, P = 0.014, sICAM-1 301.21 ± 24.80 versus 209.86 ± 17.05, P = 0.025, sE-selectin 57.37 ± 4.08 versus 45.67 ± 4.62, P = 0.045, respectively). sVCAM-1 (ng/ml) did not differ statistically among the two groups (P = 0.896). A significant reduction in hsCRP and sVCAM-1 was achieved after 6 months of metformin administration: PCOS pretreatment hsCRP 1.92 ± 0.60 versus PCOS post-treatment hsCRP 0.52 ± 0.26, P = 0.005; PCOS pretreatment sVCAM-1 668.09 ± 98.38 versus PCOS post-treatment sVCAM-1 365.82 ± 99.77, P = 0.039. CONCLUSION: These findings imply the presence of chronic inflammation in women with PCOS. Metformin decreases the levels of plasma inflammatory indices. Further investigation is required to determine whether these findings may prove to be of clinical significance for PCOS patients.

11 June 2010 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
AGAshley B. Grossman
Ashley B. Grossman

1 April 2013 in European Journal of Endocrinology
Verified
Journal Article
Closed access
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
AIAndrea M. Isidori
Andrea M. Isidori
HSHelen L Storr
Helen L Storr
FAFarhad Afshar
Farhad Afshar
AGAshley B Grossman
Ashley B Grossman
Objective: To investigate the early and late outcomes of patients with Cushing's disease (CD) submitted to a neurosurgical procedure as first-line treatment.Design: In this single-centre retrospective case notes study, 131 patients with CD with a minimum follow-up period of 6 years (124 operated by transsphenoidal surgery (TSS) and seven by the transcranial approach) were studied. Apparent immediate cure: post-operative 0900 h serum cortisol level <50 nmol/l; remission: cortisol insufficiency or restoration of ‘normal’ cortisol levels with resolution of clinical features; and recurrence: dexamethasone resistance and relapse of hypercortisolaemic features.Results: In patients operated by TSS, remission of hypercortisolaemia was found in 72.8% of 103 microadenomas and 42.9% of 21 macroadenomas, with recurrence rates 22.7 and 33.3% respectively with a 15-year mean follow-up (range, 6–29 years). Of 27 patients with microadenomas operated after 1991, with positive imaging and pathology, 93% obtained remission with 12% recurrence. In multivariate analysis, the time needed to achieve recovery of hypothalamo-pituitary–adrenal axis was the only significant predictor of recurrence; all patients who recurred showed recovery within 3 years from surgery: 31.3% of patients had total hypophysectomy with no recurrence; 42% of patients with selective adenomectomy and 26.5% with hemi–hypophysectomy showed recurrence rates of 31 and 13% respectively (χ2=6.275, P=0.03). Strict remission criteria were not superior in terms of the probability of recurrence compared with post-operative normocortisolaemia.Conclusions: Lifelong follow-up for patients with CD appears essential, particularly for patients who have shown rapid recovery of their axis. The strict criteria previously used for ‘apparent cure’ do not appear to necessarily predict a lower recurrence rate.

5 January 2015 in Neuroendocrinology
Verified
Journal Article
Open access
PDF file
ECEleftherios Chatzellis
Eleftherios Chatzellis
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
IAIoannis I. Androulakis
Ioannis I. Androulakis
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
Pituitary adenomas are common intracranial tumors that are mainly considered as benign. Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of the surrounding tissues, resistance to conventional treatment leading to early and frequent recurrences. Even more rarely, pituitary tumors can give rise to cerebrospinal or systemic metastases qualifying as pituitary carcinomas according to the latest WHO definition. In the same classification, a subset of tumors with relatively distinct histopathological features was identified and defined as atypical adenomas designated to follow a more aggressive clinical course. This classification, although clinically useful, does not provide an accurate correlation between histopathological findings and the clinical behavior of these tumors, neither is it adequate to convey the precise features of ‘aggressive' tumors. Thus, ‘aggressive' pituitary adenomas need to be properly defined with clinical, radiological, histological and molecular markers in order to identify patients at increased risk of early recurrence or subsequent tumor progression. At present, no single marker or classification system of pituitary tumor aggressiveness exists, and clinically useful information in the literature is insufficient to guide diagnostic and therapeutic decisions. Treatment of patients with aggressive pituitary tumors is challenging since conventional treatments often fail, necessitating multiple surgical procedures with additional radiotherapy. Although traditional chemotherapy applied in other neuroendocrine tumors has not been shown to be efficacious, newer agents, particularly temozolomide, have shown promising results and are currently used despite the lack of data from a randomized prospective trial. Molecular targeted therapies such as mTOR and epidermal growth factor inhibitors have also been applied and might prove to be useful in the management of these patients. In the present review, we provide information regarding the epidemiology and clinical, histopathological and molecular features of aggressive pituitary tumors using recent employed definitions. In addition, we review currently employed therapeutic means providing a therapeutic algorithm and highlight the need to identify more specific disease-related and prognostic markers and the necessity for central registration of these tumors.

1 May 2005 in European Journal of Endocrinology
Verified
Journal Article
Closed access
Evanthia Diamanti-KandarakisEvanthia Diamanti-Kandarakis
Evanthia Diamanti-Kandarakis
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
Athanase D. ProtogerouAthanase D. Protogerou
Athanase D. Protogerou
Christina PiperiChristina Piperi
Christina Piperi
CPC Papamichael
C Papamichael
MMM Mavrikakis
M Mavrikakis
Objective: The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters.Design: Descriptive clinical trial.Methods: Forty young women, 20 with PCOS and 20 normal women of similar age and body mass index were studied. Metformin (1700 mg daily) was administered for 6 months to the PCOS group. The endothelium status and the metabolic and hormonal profile were studied in both groups, as well as after metformin, by flow-mediated dilatation (FMD) on the brachial artery and by measurements of plasma endothelin-1 (ET-1) levels.Results: FMD was impaired in the PCOS group when compared with controls (3.24±0.71% vs 8.81±1.07% respectively,P< 0.0001), but this difference normalized after metformin treatment (PCOSpost-metforminvs controls: 8.17±1.26 vs 8.81±1.07%,P= 0.70) since the values significantly improved after metformin treatment (PCOSpre-metforminvs PCOSpost-metformin: 3.24±0.71 vs 8.17±1.26%,P= 0.003). ET-1 levels were significantly higher in the PCOS women compared with the control group (7.23±0.50 vs 4.99±0.69 fmol/l,P= 0.01), they improved significantly after metformin treatment (PCOSpre-metforminvs PCOSpost-metformin: 7.23±0.50 vs 3.57±0.60 fmol/l,P< 0.0001) and their difference compared with the control group was reversed (PCOSpost-metforminvs controls: 3.57±0.60 vs 4.99±0.69 fmol/l,P= 0.13). Metformin administration improved hyperandrogenemia. However, in this study, mathematical methods used to assess insulin resistance failed to show any detected alteration after treatment with metformin.Conclusions: PCOS women were found to exhibit endothelial dysfunction compared with controls, which was reversed 6 months after metformin administration.